Neuland Laboratories Posts Strong Q1 FY27 Results, Reporting Total Income of Rs 650.1 Crore
Neuland Laboratories Limited (NLL), a global manufacturer specializing in active pharmaceutical ingredients (APIs) and complex intermediates, announced its financial results for the quarter ended June 30, 2026. The company services customers in approximately 80 countries with its specialized APIs and custom manufacturing solutions.Commenting on the quarterly performance, Saharsh Davuluri, Chief Executive Officer and Managing Director of Neuland Laboratories, stated that Q1 FY27 was broadly aligned with expectations, marked by encouraging performances across both the Commercial Products (CMS) and Generics Drug Substance (GDS) businesses.
Mr. Davuluri noted that while commercial products drove a significant portion of the revenue, there are exciting developments in the pipeline projects. He mentioned the strengthening depth of customer conversations, noting that the company is engaging on broader capability-led discussions rather than focusing solely on individual projects. The management is focused on consistent delivery to build customer confidence and establish long-term partnerships. Furthermore, he indicated that investment intensity will continue to increase based on available opportunities, even as significant Capex projects are progressing according to plan.
Financial Highlights for Q1 FY27
The company's financial performance showed substantial growth compared to the same quarter in the previous fiscal year. The detailed financial summary for Neuland Laboratories Limited is provided below:| Particulars | Q1FY27 | Q1FY26 | YoY (%) | Q4FY26 | QoQ (%) |
|---|---|---|---|---|---|
| Total Income | 650.1 | 300.6 | 116.3% | 788.7 | -17.6% |
| EBITDA | 231.1 | 42.1 | 448.2% | 319.4 | -27.6% |
| EBITDA Margin | 35.5% | 14.0% | 2150 bps | 40.5% | -500 bps |
| Profit Before Tax | 197.5 | 17.4 | 1036.7% | 287.0 | -31.2% |
| PBT Margin | 30.4% | 5.8% | 2460 bps | 36.4% | -601 bps |
| Profit After Tax | 147.4 | 13.7 | 975.0% | 212.5 | -30.6% |
| PAT Margin | 22.7% | 4.6% | 1811 bps | 26.9% | -423 bps |
| EPS (Rs.) | 114.9 | 10.7 | 975.0% | 165.6 | -30.6% |
About Neuland Laboratories Limited
Neuland Labs has been involved in the manufacturing of APIs for over four decades, utilizing its cGMP facilities to serve clients across nearly 80 countries. The company has successfully developed more than 300 processes and 100 APIs. It has also filed approximately 1010+ Regulatory filings globally, including 75 active US DMFs and various approvals in the European Union (EU) and other major geographies. Its quality manufacturing commitment is supported by multiple cGMP certifications from regulatory bodies such as the U.S. FDA, EMA (EU), and PMDA (Japan).NEULANDLAB Stock Price Movement
Neuland Laboratories Limited shares surged today, closing at ₹19956 after gaining 4.03% in the post-market session. The stock achieved impressive highs, marking a significant step toward its 52-week peak and trading on a total volume of 60,067 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.